Hannonen P, Möttönen T, Hakola M, Oka M
Department of Medicine, Central Hospital, Jyväskylä, Finland.
Arthritis Rheum. 1993 Nov;36(11):1501-9. doi: 10.1002/art.1780361104.
To investigate the efficacy and tolerability of sulfasalazine (SSZ) in the treatment of early rheumatoid arthritis (RA).
Eighty patients (symptomatic disease < 12 months) were randomly assigned to treatment with SSZ or placebo for 48 weeks. Clinical, laboratory, and scintigraphic data were used to determine the effects of treatment.
SSZ was superior to placebo in reducing the laboratory features of inflammation, the clinical parameters of disease activity, as well as the scintigraphic activity in the joints. Furthermore, fewer erosive changes developed in the joints of patients receiving active treatment, but the difference between treatment groups did not reach statistical significance.
SSZ is effective in the treatment of RA, and its onset of action is rapid. The results support the view that SSZ retards the development of joint erosions. However, like other conventional disease-modifying antirheumatic drugs, its remission-inducing ability is insufficient.
探讨柳氮磺胺吡啶（SSZ）治疗早期类风湿关节炎（RA）的疗效和耐受性。
80例（症状性疾病<12个月）患者被随机分配接受SSZ或安慰剂治疗48周。临床、实验室和闪烁扫描数据用于确定治疗效果。
在降低炎症的实验室指标、疾病活动的临床参数以及关节闪烁扫描活性方面，SSZ优于安慰剂。此外，接受积极治疗的患者关节中出现的侵蚀性改变较少，但治疗组之间的差异未达到统计学意义。
SSZ治疗RA有效，且起效迅速。结果支持SSZ可延缓关节侵蚀发展的观点。然而，与其他传统抗风湿药物一样，其诱导缓解的能力不足。
